Table 1. Effect of scopolamine butylbromide on biometric and biochemical parameters.
| Parameters | NL-S | SL-S | NL-B | SL-B | Factors | ||
|---|---|---|---|---|---|---|---|
| L | T | I | |||||
| Body weight at 21 days of age (g) | 46.2 ± 1.13 | 63.81 ± 1.39 | 36.9 ± 0.81 | 53.42 ± 0.78 | **** | **** | ns |
| Body weight at 90 days of age (g) | 382.3 ± 6.8 | 421.8 ± 7.7 | 345.1 ± 10.1 | 383.5 ± 8.6 | **** | *** | ns |
| Retroperitoneal fat pad (g/100 g bw) | 1.34 ± 0.06 | 1.61 ± 0.07 | 1.12 ± 0.03 | 1.27 ± 0.05 | *** | **** | ns |
| Periepididymal fat pad (g/100 g bw) | 1.13 ± 0.04 | 1.30 ± 0.06 | 0.98 ± 0.01 | 1.00 ± 0.02 | * | **** | ns |
| Mesenteric fat pad (g/100 g bw) | 0.79 ± 0.03 | 0.97 ± 0.06 | 0.65 ± 0.02 | 0.78 ± 0.02 | *** | **** | ns |
| Food intake (g; AUC) | 214.1 ± 2.49 | 236.6 ± 1.92 | 192.0 ± 4.8 | 214.3 ± 5.86 | *** | *** | ns |
| Fasting glycemia (mg/dL) | 90.3 ± 2.05 | 100.3 ± 3.9 | 98.4 ± 1.39 | 101.2 ± 0.58 | ** | * | ns |
| Fasting insulinemia (ng/mL) | 0.21 ± 0.02 | 0.36 ± 0.03 | 0.12 ± 0.07 | 0.11 ± 0.06 | ns | **** | * |
| Fasting leptinemia (pg/mL) | 421.5 ± 88.4 | 843.4 ± 140.7 | 120.7 ± 72.7 | 314.2 ± 165.5 | ** | ** | ns |
| Kitt (%/min) | 3.11 ± 0.34 | 2.22 ± 0.08 | 2.78 ± 0.19 | 3.11 ± 0.28 | ns | ns | * |
| HOMA-IR | 1.19 ± 0.22 | 2.24 ± 0.35 | 0.90 ± 0.13 | 0.71 ± 0.13 | ns | *** | * |
All data are expressed as the mean ± SEM of 15–25 rats from 5 different litters. NL-S, normal litter rats treated with saline solution; SL-S, small litter rats treated with saline solution; NL-B, normal litter rats treated with scopolamine butylbromide; SL-B, small litter rats treated with scopolamine butylbromide. L, litter size factor; T, treatment factor; and I, interaction between litter and treatment factors. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 and ns, no significant difference, based on a two-way analysis of variance.